Graphite Bio Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The company stated in the following report that they exploit animals for product testing.
“Our research programs may fail to identify potential product candidates for clinical development for a number of reasons: our research methodology may be unsuccessful in identifying potential product candidates; our potential product candidates may be shown to have harmful side effects in preclinical in vitro experiments or animal model studies; they may not show promising signals of therapeutic effect in such experiments or studies; or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approval.” (Page 39) Read the full document
Graphite Bio, Inc. is a clinical-stage, gene editing company. The Company is developing a new class of therapies to cure a range of serious and life-threatening diseases. Its gene-editing platform allows to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations.
Company Website: https://graphitebio.com